Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Debt

The Debt of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 22, 2026 is 112.40 M EUR. In the previous year, Debt was 114.41 M EUR — a change of -1.76% (lower).

Debt

112.40 MEUR

YoY

-1.76%

Last updated:

In 2025, Laboratorios Farmaceuticos ROVI's total debt was 112.40 M EUR, a -1.76% change from the 114.41 M EUR total debt recorded in the previous year.

The Laboratorios Farmaceuticos ROVI Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
34.22 M EUR
Jan 1, 2019
84.68 M EUR
Jan 1, 2020
73.52 M EUR
Jan 1, 2021
73.15 M EUR
Jan 1, 2022
72.14 M EUR
Jan 1, 2023
65.43 M EUR
Jan 1, 2024
114.41 M EUR
Jan 1, 2025
112.40 M EUR
The Laboratorios Farmaceuticos ROVI Debt history
YEARDebtYoY
112.40 MEUR-1.76%
114.41 MEUR+74.87%
65.43 MEUR-9.30%
72.14 MEUR-1.38%
73.15 MEUR-0.51%
73.52 MEUR-13.18%
84.68 MEUR+147.42%
34.22 MEUR-20.85%
43.24 MEUR+27.94%
33.79 MEUR-21.00%
42.78 MEUR+17.83%
36.31 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Debt Details

Understanding Laboratorios Farmaceuticos ROVI's Debt Structure

Laboratorios Farmaceuticos ROVI's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Laboratorios Farmaceuticos ROVI's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Laboratorios Farmaceuticos ROVI’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Laboratorios Farmaceuticos ROVI’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Debt of Laboratorios Farmaceuticos ROVI is 112.40 M EUR in 2025.

Debt of Laboratorios Farmaceuticos ROVI changed from 114.41 M EUR to 112.40 M EUR, representing a -1.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Laboratorios Farmaceuticos ROVI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI